Published in Oncogene on September 15, 2008
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med (2012) 1.27
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 1.18
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov (2014) 1.10
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer (2015) 0.98
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer (2014) 0.97
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res (2009) 0.97
Molecular nevogenesis. Dermatol Res Pract (2011) 0.97
Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res (2010) 0.95
Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun (2015) 0.92
Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol (2013) 0.90
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol (2015) 0.89
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol (2013) 0.89
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer (2015) 0.87
Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci (2014) 0.86
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases (2011) 0.85
Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response. ACS Med Chem Lett (2014) 0.81
The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One (2014) 0.81
Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg Focus (2014) 0.81
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source. Int J Clin Exp Pathol (2012) 0.79
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget (2016) 0.76
RASopathy Gene Mutations in Melanoma. J Invest Dermatol (2016) 0.76
CRAF R391W is a melanoma driver oncogene. Sci Rep (2016) 0.75
Pulmonary squamous cell carcinoma and sorafenib. Clin Case Rep (2014) 0.75
RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells. Oncol Lett (2011) 0.75
Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options. Case Rep Oncol (2016) 0.75
Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Mod Pathol (2012) 0.75
Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. J Cancer Res Clin Oncol (2017) 0.75
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget (2016) 0.75
Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. Oncol Lett (2017) 0.75
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience. Oncotarget (2017) 0.75
Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell (1996) 10.83
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Raf-1 activates MAP kinase-kinase. Nature (1992) 7.05
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24
Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell (1996) 4.04
Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science (2004) 2.66
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A (2001) 2.58
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer (2003) 2.37
Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci U S A (1996) 2.21
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem (2005) 1.34
Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol (2001) 1.16
Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta (2004) 0.89
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J (1982) 17.98
Complete genome sequence of Methanobacterium thermoautotrophicum deltaH: functional analysis and comparative genomics. J Bacteriol (1997) 12.21
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
The frequency of chimeric molecules as a consequence of PCR co-amplification of 16S rRNA genes from different bacterial species. Microbiology (1996) 7.78
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (1996) 7.20
Frequency of formation of chimeric molecules as a consequence of PCR coamplification of 16S rRNA genes from mixed bacterial genomes. Appl Environ Microbiol (1997) 7.09
A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature (1996) 7.04
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun (1999) 6.33
Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med (1997) 5.93
A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad Sci U S A (1992) 5.60
Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol (1997) 5.49
Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice. Science (1992) 5.46
Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med (2001) 5.43
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Genetic diversity and disease control in rice. Nature (2000) 5.34
A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function. Nat Cell Biol (2000) 5.29
Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med (2001) 5.29
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex. Science (2000) 5.27
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Differential signaling via the same axon of neocortical pyramidal neurons. Proc Natl Acad Sci U S A (1998) 4.59
POWER_SAGE: comparing statistical tests for SAGE experiments. Bioinformatics (2000) 4.56
BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci (2001) 4.54
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A (1996) 4.45
Do "America's Best Hospitals" perform better for acute myocardial infarction? N Engl J Med (1999) 4.30
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 4.09
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A (1994) 3.85
Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A (1996) 3.78
Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet (1997) 3.69
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron (2001) 3.68
Signal timing across the macaque visual system. J Neurophysiol (1998) 3.66
Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol (2001) 3.63
The alternative oxidase lowers mitochondrial reactive oxygen production in plant cells. Proc Natl Acad Sci U S A (1999) 3.53
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide/adhesin. Infect Immun (1998) 3.44
Cooperative interaction of S. pombe proteins required for mating and morphogenesis. Cell (1994) 3.41
Focal adhesion kinase is involved in mechanosensing during fibroblast migration. Proc Natl Acad Sci U S A (2001) 3.41
A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature (1999) 3.40
Midzone microtubule bundles are continuously required for cytokinesis in cultured epithelial cells. J Cell Biol (1996) 3.36
Criteria and recommendations for vitamin C intake. JAMA (1999) 3.32
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Male fertility potential in terms of semen quality: a review of the past, a study of the present. Fertil Steril (1979) 3.19
Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem (1987) 3.19
The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation (1978) 3.19
Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro (2014) 3.10
Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int (2007) 3.06
Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A (1998) 3.05
Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci (2000) 3.00
Changes in reliability of synaptic function as a mechanism for plasticity. Nature (1994) 2.97
Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med (1996) 2.96
Facilitation and depression at single central synapses. Neuron (1995) 2.95
Vam3p structure reveals conserved and divergent properties of syntaxins. Nat Struct Biol (2001) 2.92
Effectiveness of laser therapy and topical desensitising agents in treating dentine hypersensitivity: a systematic review. J Oral Rehabil (2011) 2.91
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science (1997) 2.90
Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem (2000) 2.89
Coronectomy vs. total removal for third molar extraction: a systematic review. J Dent Res (2012) 2.84
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release (2001) 2.84
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83
Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. J Cell Sci (2001) 2.76
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Distinct types of rRNA operons exist in the genome of the actinomycete Thermomonospora chromogena and evidence for horizontal transfer of an entire rRNA operon. J Bacteriol (1999) 2.72
Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J (2000) 2.71
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med (1998) 2.69
Feasibility of a high-speed gamma-camera design using the high-yield-pileup-event-recovery method. J Nucl Med (2001) 2.69
A high-affinity iron permease essential for Candida albicans virulence. Science (2000) 2.68
Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell (1999) 2.68
Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A (1998) 2.68
Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na(+)-H+ exchanger. J Clin Invest (1995) 2.65
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev (2008) 2.62
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res (2001) 2.62
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis (2009) 2.56
Genome-wide identification of NBS genes in japonica rice reveals significant expansion of divergent non-TIR NBS-LRR genes. Mol Genet Genomics (2004) 2.56
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
Biology and action of colony--stimulating factor-1. Mol Reprod Dev (1997) 2.52
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51